ПРОИЗВОДНЫЕ ПУРИНА В КАЧЕСТВЕ АНТАГОНИСТОВ ПУРИНЕРГИЧЕСКИХ РЕЦЕПТОРОВ

摘要

Use of a compound of formula (I) wherein R₁ is selected from alkyl, aryl, alkoxy, aryloxy, 0thioalkyl, thioaryl, CN, halo, NR₅R₆, NR₄COR₅, NR₄CONR₅R₆, NR₄CO₂R₇ and NR₄SO₂R₇; R₂ is selected from N, O or S-containing heteroaryl groups, wherein the heteroaryl group is attached via an unsaturated carbon atom which is adjacent to one or two N, O or S-heteroatom(s), other than ortho, ortho-disubstituted heteroaryl groups; R₃ is selected from H, alkyl, COR₈, CONR₉R₁₀, CONR₈NR₉R₁₀, CO₂R₁₁ and SO₂R₁₁; R₄, R₅ and R₆ are independently selected from H, alkyl and aryl or where R₅ and R₆ are in an (NR₅R₆) group then R₅ and R₆ may be linked to form a heterocyclic ring; R₇ is selected from alkyl and aryl; R₈, R₉ and R₁₀ are independently selected from H, alkyl and aryl, or R₉ and R₁₀ may be linked to form a heterocyclic ring, or where R₈, R₉ and R₁₀ are in a (CONR₈NR₉R₁₀) group, R₈ and R₉ may be linked to form a heterocyclic group; and R₁₁, is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A_2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se.